Applications of complement factor H (CFH) in preparing anti-lung adenocarcinoma drug

A lung adenocarcinoma and drug technology, applied in the field of antitumor drugs, can solve the problems of low cure rate and high cost, and achieve the effect of reducing the degree of phosphorylation and inhibiting angiogenesis

Pending Publication Date: 2019-10-15
QIANFOSHAN HOSPITAL OF SHANDONG
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the anti-angiogenesis treatment of lung adenocarcinoma is mainly anti-VEGF, but this therapy is expensive and the cure rate is low, so it is urgent to develop new anti-angiogenesis drugs for the treatment of lung adenocarcinoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of complement factor H (CFH) in preparing anti-lung adenocarcinoma drug
  • Applications of complement factor H (CFH) in preparing anti-lung adenocarcinoma drug
  • Applications of complement factor H (CFH) in preparing anti-lung adenocarcinoma drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] 1. Materials and methods

[0051] 1. Cell lines and experimental animals

[0052] Human umbilical vein endothelial cells were purchased from Type Culture Collection (Manassas, VA), USA; human liver cancer lines were purchased from Shanghai Life Science Cell Resource Center, China. Grg1hPLAP mice were purchased from the Experimental Animal Center of Shandong University of Traditional Chinese Medicine.

[0053] 2. Cell culture

[0054] Human umbilical vein endothelial cells were cultured in DMEM medium containing 1% double antibody (100IU / mL penicillin and 100μg / mL streptomycin); Mycin), cultured in DMEM medium. The temperature of the incubator was set at 37 °C constant temperature, CO 2 The content is 5%.

[0055] 3. Obtain purified human and mouse CFH recombinant proteins

[0056] Through the E. coli protein expression system, a large amount of purified human and mouse CFH recombinant proteins were obtained, ready for subsequent in vivo and in vitro experiments: h...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure belongs to the field of anti-tumor drugs and particularly relates to applications of a complement factor H (CFH) in preparing an anti-lung adenocarcinoma drug. Related studies in the prior art show that CFH mutations can lead to increases in retinal choroidal neovascularization. As a malignant tumor, growth and metastasis of lung adenocarcinoma have a close relationship withangiogenesis. The studies are developed aiming at a function of the CFH on the angiogenesis in a lung adenocarcinoma model. Results show that the number and volume of lesions are significantly reduced and neovascularization is inhibited after injection of CFH recombinant proteins in a mouse model of the lung adenocarcinoma, indicating a therapeutic effect of the lung adenocarcinoma. Aiming at anaction mechanism of the CFH, studies show that the CFH may inhibit migration of endothelial cells by inhibiting phosphorylation of p38 in the endothelial cells. The studies demonstrate that the CFH has the therapeutic effect on the lung adenocarcinoma and is expected to be developed as the anti-lung adenocarcinoma drug.

Description

technical field [0001] The disclosure belongs to the technical field of antineoplastic drugs, and in particular relates to the application of CFH in the preparation of anti-lung adenocarcinoma drugs. Background technique [0002] The information disclosed in this Background section is only intended to increase the understanding of the general background of the disclosure, and is not necessarily to be taken as an acknowledgment or any form of suggestion that the information constitutes prior art that is already known to those skilled in the art. [0003] Lung adenocarcinoma is one of the most malignant tumors threatening human health and life in the world today. In recent years, the morbidity and mortality of lung adenocarcinoma have been increasing, surpassing squamous cell carcinoma and becoming the main type of lung cancer. At present, the treatment of lung adenocarcinoma is mainly based on surgery supplemented by radiotherapy and chemotherapy. Because lung adenocarcinom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P35/00A61P35/04
CPCA61K38/1725A61K9/0019A61P35/00A61P35/04
Inventor 刘炬范梦鸽李利群刘强王霞刘静
Owner QIANFOSHAN HOSPITAL OF SHANDONG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap